Table 3.
Effectiveness of brodalumab according to BMI classes.
| BMI ≥30 | 25 ≤BMI <30 | BMI <25 | Univariate analysis p-value | Multivariate analysis OR (CI 95%); p-value | |
|---|---|---|---|---|---|
| PASI75 w12 | 89/110 (80.91%) | 217/265 (81.89%) | 196/231 (84.85%) | 0.573 | NA |
| PASI90 w12 | 64/110 (58.18%) | 172/265 (64.91%) | 149/231 (64.50%) | 0.434 | NA |
| PASI100 w12 | 45/110 (40.91%) | 133/265 (50.19%) | 120/231 (51.95%) | 0.148 | NS |
| PASI ≤2 w12 | 83/110 (75.45%) | 189/265 (71.32%) | 167/231 (72.29%) | 0.716 | NA |
| PASI75 w24 | 96/109 (88.07%) | 241/252 (95.63%) | 207/228 (90.80%) | 0.024 a , b | b2.25 (1.06–4.79); 0.035 |
| a1.27 (1.24–6.63); 0.014 | |||||
| PASI90 w24 | 81/109 (74.31%) | 210/252 (83.33%) | 179/228 (78.51%) | 0.121 | NS |
| PASI100 w24 | 58/109 (53.21%) | 169/252 (67.06%) | 139/228 (60.96%) | 0.040 a | a1.72 (1.08–2.73); 0.022 |
| PASI ≤2 w24 | 98/109 (89.91%) | 229/252 (90.87%) | 198/228 (86.84%) | 0.352 | NA |
| PASI75 w52 | 88/100 (88%) | 224/240 (93.33%) | 198/213 (92.96%) | 0.217 | NA |
| PASI90 w52 | 78/100 (78%) | 201/240 (83.75%) | 179/213 (84.04%) | 0.368 | NA |
| PASI100 w52 | 59/100 (59%) | 169/240 (70.42%) | 150/213 (70.42%) | 0.085 | a1.65 (1.01–2.69); 0.046 |
| PASI ≤2 w52 | 88/100 (88%) | 213/240 (88.75%) | 193/213 (90.61%) | 0.727 | NA |
| PASI75 w104 | 45/49 (91.84%) | 130/137 (94.89%) | 108/118 (91.53%) | 0.533 | NA |
| PASI90 w104 | 40/49 (81.63%) | 117/137 (85.40%) | 102/118 (86.44%) | 0.725 | NA |
| PASI100 w104 | 29/49 (59.18%) | 97/137 (70.80%) | 82/118 (69.49%) | 0.308 | NA |
| PASI ≤2 w104 | 45/49 (91.84%) | 128/137 (93.43%) | 109/118 (92.37%) | 0.914 | NA |
| PASI75 w156 | 13/14 (92.86%) | 53/55 (96.36%) | 44/46 (95.65%) | 0.848 | NA |
| PASI90 w156 | 12/14 (85.71%) | 45/55 (81.82%) | 39/46 (84.78%) | 0.897 | NA |
| PASI100 w156 | 9/14 (64.29%) | 38/55 (69.09%) | 28/46 60.87(%) | 0.686 | NA |
| PASI ≤2 w156 | 13/14 (92.86%) | 50/55 (90.91%) | 42/46 (91.30%) | 0.974 | NA |
BMI, body mass index; OR, odds ratio; CI, confidence interval; NA, not applicable (multivariate analysis was not performed for these variables, as the p-value at univariate analysis was ≥0.2); NS, not significant.
a
Overweight versus obese patients.
b
Overweight versus normal-weight patients.